Signe Borgquist

Chair Professor of Oncology. Breast cancer specialist. Translational cancer researcher. @oncaarhus. @AUHdk. @AarhusUni. @lunduniversity @obecare

[Breastcancer.org @Breastcancerorg]

At #ESMOBreast2025, Dr. @SixtenHarborg shared an analysis from the Nurses’ Health Study showing that weight gain after diagnosis may raise #breastcancer death risk. Study followed 6,800+ women between 1978 - 2018, with follow-up ranging from 4–15 years.
🔗https://t.co/YrnU7QyuFw

[Signe Borgquist @signeborgquist]

@ErikaHamilton9 @myESMO Thank you for highlighting this important study by @SixtenHarborg

[Christine Desmedt @ChristineDesme2]

Obesity➡️ worse prognosis & different biology #breastcancer.
Still, BMI is only reported in 8% of 495 trials we reviewed. More research needed to study impact of BMI on treatment efficacy and toxicity🙏 !
@Josephine_VC @VanBaelenKaren @OncoAlert
https://t.co/5oRStoBQP5

[Signe Borgquist @signeborgquist]

@KaKjaergaard @DeeCroninFenton 👏🏼👏🏼 Brilliant work - clinically important! Metabolic screening among cancer patients seems relevant!
@DCEAarhus @dr_rwt @ToftSorensen
@oncaarhus

[DocWire News @mydocwire]

🆕 #Breastcancer survivors have a modestly increased risk of #type2diabetes, largely driven by breast cancer treatment. #t2d #ESMOBreast24 #oncologynews @myESMO

📰 Find Out More: https://t.co/TkXX7ZzmOv

[Signe Borgquist @signeborgquist]

Thank you for highlighting our research results - timely to consider metabolic screening among cancer patients! @jonasbh93 @jensbruu @ncfoDK @StenoAarhusRes @SDCOdense

[DocWire News @mydocwire]

📰 Patients with #breastcancer who have high levels of glycosylated hemoglobin have an increased risk of recurrence and death. #HbA1c #ESMOBreast24

👉 Read More: https://t.co/07oJhjQoLg

@myESMO #oncologynews @jensbruu

[DocWire News @mydocwire]

📄 #Breastcancer survivors with #metabolicsyndrome have shorter disease-free survival than those without metabolic syndrome. #ESMOBreast24 #oncologynews @myESMO

🗞️ Read More: https://t.co/tIjzgAopYG

[Paolo Tarantino @PTarantinoMD]

Important point by @ErikaHamilton9. A common questions from pts is: what should I take (or eat) to reduce my risk of recurrence? The answer to this question should not come from retrospective studies, often burdened by confounding bias, but should derive from RCTs. #ESMOBreast24

[Signe Borgquist @signeborgquist]

@SixtenHarborg @mydocwire Breast cancer patients may need metabolic screening and treatment of potential metabolic disorders💊

[Sixten @SixtenHarborg]

So happy to be at the #ESMOBreast24 and share our results on the impact of metabolic syndrome on breast cancer outcomes🔬

BC patients with metabolic syndrome have poorer outcomes compared to their peers without metabolic syndrome ‼️

Read @mydocwire coverage of our study📰

[Elisa Agostinetto @ElisaAgostinett]

At #ESMOBreast24:

In a Danish population-based cohort 🇩🇰 study statin use ⬇️ breast cancer mortality 💊

Validation in prospective randomized trials is needed‼️

A phase 3 trial is ongoing https://t.co/4NBPap9N4G

@OncoAlert

[Signe Borgquist @signeborgquist]

@ElisaAgostinett @OncoAlert Thank you for acknowledging our current work & the importance of phase III trials in #statins and #breastcancer See: https://t.co/AxbJriBSjf

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Emulated target trial looking at #statins in early #bcsm

Those that received statins had ⬆️ survival.

🎯 Question is what other healthy behaviors are associated with statin use?

Hard to conclude much with study design, MASTER randomized will help.

#ESMOBreast24
@myESMO

[Signe Borgquist @signeborgquist]

@ErikaHamilton9 @myESMO Thanks a lot - doing our best to provide the evidence needed for statins in breast cancer in the MASTER trial: https://t.co/AxbJriBSjf

[Signe Borgquist @signeborgquist]

@PTarantinoMD @ErikaHamilton9 Thank you for highlighting our efforts - MASTER, academic phase III trial w statins vs placebo: https://t.co/AxbJriBSjf

[Signe Borgquist @signeborgquist]

Great morning at #ESMOBreast24 - awaiting our talented PhD-student @SixtenHarborg at @oncaarhus to talk - emulated target trial with statins in #breastcancer

[Signe Borgquist @signeborgquist]

Enjoying ESMO Breast 2024 with these amazing talents🇩🇪☀️💖
@jonasbh93 @SixtenHarborg @KaKjaergaard @Jeppe_Skovbjerg @KirstenWoolpert
#ESMOBreast24

[Signe Borgquist @signeborgquist]

Sikke en fantastisk dag! Samarbejde er ordet!

[Department of Oncology, Aarhus University Hospital @oncaarhus]

Glimt fra ph.d.-gruppens udflugt til Kræftens Bekæmpelses forskningsenhed. Det var en spændende og lærerig dag med formålet at fremme fremtidigt samarbejde på tværs af vores organisationer. Stort tak for invitationen. @cancer_dk #DanishCancerInstitute

[Signe Borgquist @signeborgquist]

Attending #SABCS2023 remotely from lovely @SkagenDenmark with this superb team of colleagues @BOffersen @TrineTramm @SixtenHarborg @jonasbh93 @Jeppe_Skovbjerg @kristinehogsbj1 @PSkovlund Martin & Lærke @oncaarhus @AarhusUni

[Signe Borgquist @signeborgquist]

@oncaarhus @MarieTvilum @HealthAarhusUni @AUHdk Lots of happiness and brightness around @MarieTvilum - again, my warmest congratulations on the great achievement, dear Marie🌹

[Sixten @SixtenHarborg]

Obesity Linked to Increased Recurrence Rates in Breast Cancer https://t.co/rnXaoVzHch

Thanks @curetoday for the chat and for featuring our latest paper 📄